Immunocore Holdings (IMCR) said Monday it has dosed the first patient in a phase 1 trial of IMC-P115C, a half-life extended Immune mobilizing monoclonal T-cell receptor against cancer, or ImmTAC, candidate.
The drug candidate was developed to improve patient convenience by reducing the frequency of treatment administration, the company said.
The phase 1 trial will assess the safety, pharmacokinetics and clinical activity of IMC-P115C in patients with a specific type of advanced solid tumor.
According to the company, ImmTAC molecules are designed to redirect the immune system to recognize and kill cancerous cells.
Shares of the company rose more than 5% in recent premarket activity Monday.
Price: 30.00, Change: +1.67, Percent Change: +5.91
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.